KFG Wealth Management LLC Sells 100 Shares of Eli Lilly and Company (NYSE:LLY)

KFG Wealth Management LLC reduced its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 16.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 492 shares of the company’s stock after selling 100 shares during the quarter. KFG Wealth Management LLC’s holdings in Eli Lilly and Company were worth $287,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Lipe & Dalton bought a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $26,000. Thompson Investment Management Inc. acquired a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at approximately $27,000. Retirement Group LLC boosted its holdings in shares of Eli Lilly and Company by 159.1% in the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after buying an additional 35 shares during the last quarter. Cornerstone Planning Group LLC acquired a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $33,000. Finally, Legacy Financial Group LLC acquired a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at approximately $35,000. 82.53% of the stock is owned by institutional investors.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 54,032 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $645.07, for a total transaction of $34,854,422.24. Following the completion of the sale, the insider now directly owns 99,488,598 shares of the company’s stock, valued at approximately $64,177,109,911.86. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Morgan Stanley boosted their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a report on Friday, February 16th. JPMorgan Chase & Co. boosted their price target on Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a report on Friday, March 15th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $850.00 price objective on shares of Eli Lilly and Company in a research note on Friday, March 22nd. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Stock Down 2.6 %

Shares of NYSE:LLY traded down $19.64 during trading on Friday, reaching $726.31. 3,486,055 shares of the stock were exchanged, compared to its average volume of 3,073,465. The firm has a market cap of $690.11 billion, a price-to-earnings ratio of 125.67, a price-to-earnings-growth ratio of 1.64 and a beta of 0.34. The stock has a fifty day moving average of $764.24 and a two-hundred day moving average of $658.28. Eli Lilly and Company has a 1-year low of $369.76 and a 1-year high of $800.78. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. The business had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. Eli Lilly and Company’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.09 EPS. Research analysts anticipate that Eli Lilly and Company will post 12.52 earnings per share for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.